Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banwell, B. L.
Right arrow Articles by Engel, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banwell, B. L.
Right arrow Articles by Engel, A. G.
Neurology 2000;54:1033-1041
© 2000 American Academy of Neurology
Articles

{alpha}B-Crystallin immunolocalization yields new insights into inclusion body myositis

Brenda L. Banwell, MD and Andrew G. Engel, MD

From the Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN.

Address correspondence and reprint requests to Dr. A.G. Engel, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

OBJECTIVE: To study the expression of the small heat shock protein, {alpha}B-crystallin ({alpha}BC), in inclusion body myositis (IBM).

BACKGROUND: In humans, {alpha}BC is constitutively expressed in the eye lens, muscle, and heart, but not in lymphoid tissues. Induced expression of {alpha}BC occurs under metabolic stress, in virus-infected lymphocytes, and in degenerative brain lesions, including neurofibrillary tangles and senile plaques in AD. The previously reported pathologic similarities between AD and IBM prompted us to study {alpha}BC expression in IBM.

METHODS: Immunolocalization of {alpha}BC in muscle of 11 patients with IBM, 50 patients with other muscle diseases, and 4 controls; and quantitative analysis of the frequency of fibers with 1) increased {alpha}BC expression in IBM and polymyositis and 2) structural abnormality (vacuolated, non-necrotic and invaded by mononuclear cells, Congo red–positive, SMI-31 positive, and ubiquitin positive) in IBM.

RESULTS: We detected enhanced expression of {alpha}BC not only in all structurally abnormal IBM fibers, but also, and with severalfold higher frequency, in IBM fibers without significant structural abnormality (X fibers) (p values in paired t-tests < 0.001). We also found enhanced {alpha}BC in abnormal fibers in other diseases; X fibers, however, were extremely sparse or absent, except in two atypical cases of polymyositis refractory to immunotherapy.

CONCLUSION: That the X fibers are much more frequent than the structurally abnormal fibers in IBM points to a pathogenic stressor acting upstream to the development of structural abnormalities. The identification of this stressor is now of paramount importance for deciphering the enigma of IBM.

Key words: {alpha}B-crystallin—Inclusion body myositis—Immunolocalization—T-cell response—Myopathies.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
I E Muth, K Barthel, M Bahr, M C Dalakas, and J Schmidt
Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of {alpha}B-crystallin is associated with amyloid precursor protein and accumulation of {beta}-amyloid
J. Neurol. Neurosurg. Psychiatry, December 1, 2009; 80(12): 1344 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A A Amato and R J Barohn
Inclusion body myositis: old and new concepts
J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. A Greenberg
How citation distortions create unfounded authority: analysis of a citation network
BMJ, July 23, 2009; 339(jul20_3): b2680 - b2680.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, et al.
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
Brain, June 1, 2009; 132(6): 1536 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla
Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model
J. Neurosci., May 13, 2009; 29(19): 6132 - 6141.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Schmidt, K. Barthel, A. Wrede, M. Salajegheh, M. Bahr, and M. C. Dalakas
Interrelation of inflammation and APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid in skeletal muscle
Brain, May 1, 2008; 131(5): 1228 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Fonte, D. R. Kipp, J. Yerg III, D. Merin, M. Forrestal, E. Wagner, C. M. Roberts, and C. D. Link
Suppression of in Vivo -Amyloid Peptide Toxicity by Overexpression of the HSP-16.2 Small Chaperone Protein
J. Biol. Chem., January 11, 2008; 283(2): 784 - 791.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. A. Greenberg
Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications
Neurology, November 20, 2007; 69(21): 2008 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Askanas and W. K. Engel
Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition
Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. J. Macario and E. C. de Macario
Sick Chaperones, Cellular Stress, and Disease
N. Engl. J. Med., October 6, 2005; 353(14): 1489 - 1501.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. Nakano, A. Shinde, H. Ito, H. Ito, and H. Kusaka
Messenger RNA degradation may be inhibited in sporadic inclusion body myositis
Neurology, August 9, 2005; 65(3): 420 - 425.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Nakano, A. Shinde, H. Ito, H. Ito, and H. Kusaka
MAP kinase phosphatase-1 is induced in abnormal fibers in inclusion body myositis
Neurology, August 12, 2003; 61(3): 322 - 326.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M C DALAKAS
Progress in inflammatory myopathies: good but not good enough
J. Neurol. Neurosurg. Psychiatry, May 1, 2001; 70(5): 569 - 573.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. Nakano, A. Shinde, S. Kawashima, S. Nakamura, I. Akiguchi, and J. Kimura
Inclusion body myositis: Expression of extracellular signal-regulated kinase and its substrate
Neurology, January 9, 2001; 56(1): 87 - 93.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. Amemiya, R. P. Granger, and M. C. Dalakas
Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: Studies in repeated muscle biopsies
Brain, October 1, 2000; 123(10): 2030 - 2039.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Karpati and R. Hohlfeld
Biologically stressed muscle fibers in sporadic IBM: A clue for the enigmatic etiology?
Neurology, March 14, 2000; 54(5): 1020 - 1021.
[Full Text] [PDF]